Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms

Valeant Pharmaceuticals International (NYSE: VRX ) announced today that the company has reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms of the revised agreement, Galderma will continue to supply Restylane® and Perlane® to Valeant, under the terms and conditions